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Abstract
Background: Induced mutagenesis in utero is likely to have life-long repercussions for the exposed
fetus, affecting survival, birth weight and susceptibility to both childhood and adult-onset diseases,
such as cancer. In the general population, such exposures are likely to be a consequence of the
lifestyle choices of the parents, with exposure to tobacco smoke one of the most pervasive and
easily documented. Previous studies attempting to establish a direct link between active smoking
and levels of somatic mutation have largely discounted the effects of passive or secondary
exposure, and have produced contradictory results.
Methods: Data from three studies of possible smoking effects on in utero mutagenesis at the HPRT
locus were compiled and reanalyzed, alone and in combination. Where possible, passive exposure
to environmental tobacco smoke was considered as a separate category of exposure, rather than
being included in the non-smoking controls. Molecular spectra from these studies were reanalyzed
after adjustment for reported mutation frequencies from the individual studies and the entire data
set.
Results: A series of related studies on mutation at the X-linked HPRT locus in human newborn
cord blood samples has led to the novel conclusion that only passive maternal exposure to tobacco
mutagens has a significant effect on the developing baby. We performed a pooled analysis of the
complete data from these studies, at the levels of both induced mutation frequency and the
resulting mutational spectrum.
Conclusion: Our analysis reveals a more commonsensical, yet no less cautionary result: both
active maternal smoking and secondary maternal exposure produce quantitatively and qualitatively
indistinguishable increases in fetal HPRT  mutation. Further, it appears that this effect is not
perceptibly ameliorated if the mother adjusts her behavior (i.e. stops smoking) when pregnancy is
confirmed, although this conclusion may also be affected by continued passive exposure.
Background
It has now been unambiguously established that cigarette
smoking causes lung and other cancers, and that exposure
to secondary tobacco smoke exhaled by smokers also has
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a causal role in carcinogenesis [1,2]. Carcinogenic smoke
metabolites act primarily as genotoxicants by direct DNA
adduction as well as by producing oxidative DNA dam-
age. These DNA adducts therefore act as effective biologi-
cal markers of tobacco smoke carcinogen exposure,
integrating differences in metabolic capacity that modify
the activation of such chemicals in the body. A subset of
these adducts elude the cellular DNA repair systems,
which also exhibit interindividual functional variation,
persisting through DNA replication to produce mutations
[reviewed in [3]]. Thus, induced mutations in surrogate
reporter genes can also act as biomarkers of tobacco
smoke carcinogenesis, although there is an attenuation of
the genotoxic "signal". Induced mutagenesis is therefore
more a measure of biological effect than a quantification
of exposure [4]. The HPRT  assay is the most widely
applied measure of in vivo mutagenesis and has often been
used as an intermediate biomarker of biological effect in
exposed populations [5,6]. Although most individual
studies and meta-analyses have demonstrated a signifi-
cant induction of in vivo mutation in smokers [6,7], there
are still exceptions [8-10]. Similarly, there are contradic-
tory studies on the effect of maternal smoking on muta-
tion frequencies in their unborn offspring [11,12].
Maternal tobacco smoking has been associated with pre-
mature delivery, low birth weight, deficient lung and neu-
rological function, and increased risk of perinatal
mortality [3,13-16]. During differentiation and develop-
ment, specific cell types are sequentially induced to prolif-
erate, when they become hypersensitive to cytotoxic
agents, resulting in the observed dependence of teratolog-
ical effects upon timing of exposure [17]. Although it has
not been proven, there is great concern that the develop-
ing fetus might also be hypersensitive to genotoxic agents,
producing many oncogenically "initiated" cells which
might then expand during the fulfillment of the develop-
mental program. Many studies have demonstrated that
tobacco carcinogens cross the placenta [18,19], so that
their mutagenic effects might be detected in the offspring.
Additionally, in the particular case of the HPRT  assay,
cord blood mutation frequencies (Mf) measured at birth
are approximately 10-fold lower than that predicted from
age-dependence data in older children and adults, with a
correspondingly low variance, such that cord blood HPRT
mutation measurements should be uniquely sensitive to
inductive effects [20].
A number of studies have been undertaken to determine
whether maternal "lifestyle" factors influence in utero
mutagenesis, often specifically targeting smoking as the
putative source of genotoxicants. Indeed, two studies
from essentially the same laboratories have come to very
different conclusions on this question: first, that there was
no detectable effect of maternal tobacco smoke exposure
on HPRT Mf in cord blood [21], and second, that despite
the fact that there was no increase in the Mf of children
born to mothers who had been exposed to environmental
tobacco smoke, there was a significant shift in the muta-
tional spectrum in these children, indicating that different
mechanisms of mutation were responsible for their
observed Mf [22,23]. We now report a pooled reanalysis of
these data, which provides evidence for a more coherent
interpretation of these studies. We find that children of
active smokers, women who quit smoking when they
found they were pregnant and women who were exposed
only to secondary smoke during their pregnancy all had
similar, significant increases in T-lymphocyte HPRT  Mf
over offspring of women who reported neither active nor
secondary exposure. These data provide a rationale for a
shift in the HPRT mutational spectra in children of moth-
ers passively exposed to environmental tobacco smoke.
These data also provide evidence that secondary smoking
exposure can have effects indistinguishable from active
smoking. This result is discussed in the context of other
attempts to document the genotoxic effects of tobacco
smoke, and with regard to our own observations in
women who attempted to protect their unborn child by
quitting smoking during pregnancy.
Methods
Data
All HPRT assays were performed by the method of O'Neill
et al [24] in the laboratories of R.J. Albertini, B.A. Finette
and colleagues at the University of Vermont. Exposure his-
tories were obtained by questionnaire at postpartum
interviews. Women were considered to be passively
exposed if they lived or worked in the presence of active
smokers. Tobacco carcinogen biomarkers were not specif-
ically determined in the first study [21], although biomar-
kers of drug abuse were concurrently monitored and
corroborated interview data, and in previous studies in
the same hospital population serum thiocyanate and coti-
nine levels corroborated histories of active smoking
[25,26]. Tobacco smoke exposure in the second study
[22,23] was assessed by measurement of cord blood coti-
nine levels [27]. The authors identified two subjects
whose cotinine levels were not in agreement with their
self-reported tobacco smoke exposure group (MFS72
from the passive exposure group and MFS30 from the
"quitters" both had cotinine levels characteristic of active
smokers) and excluded them from subsequent analysis. In
addition, subject MFS99 from the actively smoking group
had undetectable cotinine levels, and cotinine levels were
not performed on MFS9 from the passively exposed
group. These data were analyzed three ways, first retaining
these samples in their self-reported categories, in keeping
with the assignment of the data from Manchester et al
[21], second, deleting them from the analysis as perBMC Pediatrics 2005, 5:20 http://www.biomedcentral.com/1471-2431/5/20
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Finette et al [22,23], and third, reassigning these samples
to the category indicated by their cotinine results.
Data from the study of Manchester et al [21] was obtained
by pooling their two data sets identified as "University
Hospital Colorado" (tobacco smoke exposure was ascer-
tained in only 60 of the 67 subjects analyzed) and "Private
Hospital Colorado". Data from the second study is largely
that of Finette et al [22] supplemented with new subjects
MFS3, MFS14, MFS36, MFS83 and MFS89 in the non-
smoking, non-passively exposed group, the addition of
MFS12 to the passively exposed group (subsequently
removed as an outlier), and the adjustment of the Mf of
MFS65 in the passively exposed group, all reported in
Finette et al [23].
Two outliers (defined as having HPRT  Mf greater than
three standard deviations higher than the population)
had been previously identified, one in each of these stud-
ies. These values both remained outliers in their respective
data sets after ln transformation, but only the highest out-
lier remained significant after pooling the transformed
data from the two studies. Except where specifically men-
tioned in the text, inclusion or exclusion of these subjects
did not affect the statistical analyses performed on these
populations.
Statistical analysis
Pairwise analyses were performed on native and ln trans-
formed data using Student's t test assuming equal variance
from the statistical toolpack of Microsoft Excel. Nonpara-
metric analyses were performed using the Mann-Whitney
U test available in MiniTab. Except where noted, all three
analyses yielded equivalent results regarding significance.
Overall smoking effects were evaluated using single factor
ANOVA from Excel.
Comparisons of distributions were performed by the chi-
square test in MiniTab. Mutations were considered to be
independent if they arose uniquely and/or demonstrated
a unique rearrangement of the T-cell receptor β and γ
genes [28]. In all three mutational spectra studies consid-
ered, mutants were derived from a subset of subjects and,
in a small minority of cases, multiple clones were ana-
lyzed from the same individual. In the McGinness et al
[29] and Manchester et al [21] studies molecular analyses
consisted of Southern blotting with a full length human
HPRT cDNA as probe. In the Finette et al [23] study, all
but one mutant was defined more completely by sequenc-
ing of the base change(s) involved or of the deletion
breakpoints.
Results and discussion
Study 1
The first set of data was derived from a cohort of 70 new-
borns born at two hospitals in Denver, Colorado [21].
HPRT Mf were determined on cord blood samples using
the clonogenic assay. Smoking status was initially sepa-
rated into three categories: active smokers, active smokers
who quit after confirmation of pregnancy (quitters), and
non-smokers. In a secondary analysis, non-smokers were
then broken out into those likely to have ongoing expo-
sure to environmental tobacco smoke and those actively
avoiding passive or secondary smoking exposure. These
categories were based on the paradigm that the genotoxic
effects of secondary smoke should be intermediate
between those of non-smokers with no secondary expo-
sure and active smokers, and their exposure levels and
therefore induced mutation frequencies were expected to
be closer to those of the non-exposed population than
those of the active smokers. Thus, the HPRT Mf of the total
non-smoking population (with and without evidence of
passive exposure, although clearly skewed towards the
passively exposed population, which contributed 20 of
the 28 subjects in this category) was used as the basis of
comparison for the smoking and quitting groups, and nei-
ther was found to have a significant induction of HPRT
mutants. In the present investigation, we have combined
these primary and secondary analyses, using only the non-
smokers with no evidence of secondary tobacco smoke
exposure as the basis of comparison (this was the only cat-
egory in the original study reported as having a signifi-
cantly lower Mf). These data are summarized in Table 1,
panel a.
One outlier was identified in this data set, defined as an
individual with an HPRT Mf greater than 3 standard devi-
ations higher than the mean for the population. This indi-
vidual was born to a women who quit smoking during her
pregnancy, and had an Mf of 14.7 × 10-6, 10-fold higher
than the mean of the entire population, 15-fold higher
than the median value.
By breaking the "non-smoking" population into those
with and without evidence of environmental tobacco
smoke exposure, and using those with no evidence of
such passive exposure as baseline, we now show both sig-
nificant effects of tobacco smoke exposure overall in this
population, as well as significant inductions in all three
exposed categories. Moreover, the HPRT Mf in the three
exposed populations were not significantly different from
one another (pairwise P values ranged from 0.09 to 0.75),
unless the outlier was included in the analysis, in which
case the "quitters" were significantly higher than all three
of the other groups.BMC Pediatrics 2005, 5:20 http://www.biomedcentral.com/1471-2431/5/20
Page 4 of 8
(page number not for citation purposes)
Study 2
The second set of data is derived from two related publi-
cations [22,23], that were designed as follow-ups to those
of McGinniss et al [11] and Manchester et al [21]. In the
former study, newborns in Burlington, Vermont, demon-
strated no detectable effect of maternal active smoking on
cord blood HPRT Mf, although passive exposure was not
considered, and therefore might have been a confounding
factor. Subjects for the follow-up studies were recruited
from the same university-affiliated hospital in Vermont,
and had similar HPRT Mf. In this study, passive exposure
was assessed by interview and ongoing tobacco smoke
exposure was estimated by measurement of cotinine lev-
els in the cord blood. In general, these cotinine measure-
ments confirmed the smoking exposure assignments
based on the interviews. These data are summarized in
Table 1, panel b.
This population also contained an outlier, this one in the
passively exposed group, with an Mf of 45.3 × 10-6, 30-fold
higher than the average of the population and 70-fold
higher than the median value.
Finette et al [22,23] reported on two different but overlap-
ping subsets of these data, and found no evidence of any
type of tobacco smoke exposure affecting HPRT Mf. Anal-
ysis of the entire data set, as summarized in Table 1, panel
b, confirms these results. Indeed, only if the extreme out-
lier is included in the analysis is any comparison even
close to significant (unexposed vs. passively exposed, P =
0.063).
Pooled data
These two studies examined similarly sized populations,
and both failed initially to demonstrate an influence of
tobacco smoke exposure on newborn HPRT Mf. These two
sets of subjects are geographically distinct, and may differ
in other ways, but this cannot be assessed from the pub-
lished data. No other factor was reported to have signifi-
cantly affected newborn HPRT  Mf  in either study,
however. The Mf of the unexposed populations from the
two studies are not significantly different from one
another (P = 0.48), but the combined exposed population
from the Colorado population is 1.5-fold higher than the
equivalent population from the Vermont studies, which is
significant (P < 0.001). This difference has been attributed
to maternal environmental and socioeconomic factors,
but nothing has been proven. The distribution of samples
between the four smoking exposure categories differs sig-
nificantly between the two studies (P = 0.044), with the
major disparity being the proportion of active smokers
(39% in the Manchester et al study [21] vs. 17% in the
Finette et al studies [22,23], P = 0.006). It is tempting to
invoke this difference in population distribution to
Table 1: HPRT Mf in newborns with and without exposure to tobacco smoke metabolites in utero
HPRT Mf (× 10-6)
maternal exposure N mean ± SD median range P1,2 P2,3
a) data from Manchester et al [21]
unexposed 18 0.76 ± 0.50 0.61 0.14 – 1.9
passive only 20 1.60 ± 1.43 1.35 0.30 – 5.3 0.021
quit during pregnancy4 4 1.85 ± 1.16 1.60 0.35 – 3.2 0.004
smoked throughout 27 1.36 ± 0.99 0.98 0.28 – 3.5 0.019 0.012
b) data from Finette et al [22,23]
unexposed 26 0.72 ± 0.53 0.52 0.05 – 1.9
passive only5 22 1.18 ± 1.28 0.67 0.10 – 5.1 0.14
quit during pregnancy 8 0.79 ± 0.46 0.69 0.18 – 1.8 0.51
smoked throughout 12 0.71 ± 0.51 0.56 0.14 – 1.8 0.73 0.47
c) pooled data
unexposed 44 0.73 ± 0.51 0.60 0.05 – 1.9
passive only5 42 1.38 ± 1.36 0.87 0.10 – 5.3 0.006
quit during pregnancy4 12 1.27 ± 0.93 0.91 0.18 – 3.2 0.014
smoked throughout 39 1.16 ± 0.91 0.87 0.14 – 3.5 0.007 0.007
1specific exposed group vs. unexposed HPRT Mf from single factor ANOVA on ln transformed data
2since these four tests were performed simultaneously, to preserve an overall α of 0.05, the threshold for significance of each individual test should 
be set at P = 0.0125, or, if exposure is only tested for an induction of mutation, P = 0.025
3overall single factor ANOVA on ln transformed data
4excluding outlier with HPRT Mf of 14.7 × 10-6
5excluding outlier with HPRT Mf of 45.3 × 10-6BMC Pediatrics 2005, 5:20 http://www.biomedcentral.com/1471-2431/5/20
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explain the higher overall Mf of the Colorado population
(mean 1.32 × 10-6, median 0.96 × 10-6, range 0.14–5.3 ×
10-6) than the population from Vermont (mean 0.89 × 10-
6, median 0.64 × 10-6, range 0.05–5.1 × 10-6) (P = 0.006)
when the outliers are not included in the analysis. How-
ever, the proportion of all tobacco-exposed individuals
(including active smokers, quitters and passively exposed
mothers) is not significantly different between the two
populations (74% vs. 62%, P = 0.66). The HPRT Mf for the
pooled data set are given in Table 1, panel c.
Analysis of the pooled data from these two studies essen-
tially reiterates the results of the reanalysis of the data
from Manchester et al [21] discussed above: all three
groups of tobacco exposed newborns have HPRT Mf sig-
nificantly higher than the unexposed group, and there is
no significant difference between the levels of induced
mutation amongst the three exposed populations. These
data indicate that tobacco smoke exposure in utero does
induce detectable HPRT mutants in the fetus, and that
passive maternal exposure has a similar teratogenic effect
as active maternal smoking, a finding that is not unprece-
dented [30].
HPRT molecular spectra
Despite the lack of evidence for a mutagenic effect of
tobacco smoke in their newborn cord bloods, Finette et al
[23] nevertheless examined the molecular spectrum of
HPRT mutants in two of their subpopulations, those with-
out evidence of any maternal tobacco smoke exposure
and those with passive exposure only. The mutations were
classified as a) small, intragenic changes, b) gene rear-
rangements or deletions, or c) exon 2/3 deletions charac-
teristic of illegitimate VDJ recombination (especially in
newborn populations [23,31,32]). These data, summa-
rized in Table 2, panel a, suggest a shift in the spectrum of
the exposed population to significantly higher propor-
tions of both small mutations and deletions attributable
to VDJ recombination. Since there was no overall increase
in HPRT Mf in this population, however, the exposed pop-
ulation also had a compensatory significantly lower pro-
portion of non-VDJ mediated deletions and
rearrangements, suggesting a protective effect of tobacco
smoke exposure on these types of mutagenic events. We
have found that the need to invoke such a protective effect
is reduced if these data are put in perspective of the related
studies mentioned above [21,23] and if mutation fre-
quencies are used to normalize the distributions.
Table 2: HPRT mutational spectra in newborns with and without exposure to tobacco smoke metabolites in utero
a) distribution of mutant clones
maternal 
exposure
study total independent 
mutants
small mutations 
(%)
deletions, rearrangements 
(%)
VDJ recombinant 
deletions (%)
P1
unexposed Finette et al [23] 30 10 (33) 14 (47) 6 (20)
mixed McGinniss et al [11] 41 7 (17) 14 (34) 20 (49) 0.039
mixed Manchester et al [21] 38 13 (34) 16 (42) 9 (24) 0.91
passively exposed Finette et al [23] 35 17 (49) 6 (17) 12 (34) 0.036
b) mutation frequencies for three classes of mutants based on individual studies
maternal 
exposure
study overall mean 
Mf ± SD (× 10-6)
small mutations 
Mf (× 10-6)
deletions, rearrangements 
Mf (× 10-6)
VDJ recombinant 
deletions Mf (× 10-6)
P2
unexposed Finette et al [22,23] 0.72 ± 0.53 0.24 0.34 0.14
mixed McGinniss et al [11] 0.64 ± 0.40 0.11 0.22 0.31 0.003
mixed Manchester et al [21] 1.32 ± 1.093 0.45 0.56 0.31 < 0.001
passively exposed Finette et al [22,23] 1.18 ± 1.284 0.57 0.20 0.40 0.002
c) mutation frequencies for three classes of mutants based on pooled data5
unexposed Finette et al [22,23] 0.73 ± 0.51 0.24 0.34 0.15
mixed McGinniss et al [11] 0.99 ± 0.95 0.17 0.34 0.48 0.008
mixed Manchester et al [21] 0.99 ± 0.953 0.34 0.42 0.24 0.037
passively exposed Finette et al [22,23] 1.38 ± 1.364 0.67 0.24 0.47 < 0.001
1χ2
2t tests on ln transformed data
3excluding outlier with HPRT Mf of 14.7 × 10-6
4excluding outlier with HPRT Mf of 45.3 × 10-6
5for the purposes of this analysis the data of McGinniss et al [11] was pooled with that of Manchester et al [21] and Finette et al [22,23] to yield a 
single Mf.BMC Pediatrics 2005, 5:20 http://www.biomedcentral.com/1471-2431/5/20
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Summaries of the HPRT  mutational spectra generated
from the earlier analysis of a newborn population from
Vermont [29] and the Colorado UHD population [21] are
also presented in Table 2a. These spectra were generated
from mutants without regard for their potential tobacco
smoke exposure, so are classified as "mixed". The popula-
tion of McGinniss et al [11,29] contained only 20% active
smokers, however, while the incidence of passive expo-
sure of the remaining 80% of the population was not esti-
mated. 45% of the population reported in Manchester et
al  [21] actively smoked throughout pregnancy, and
another 33% reported ongoing exposure to secondary
tobacco smoke; only 13% could be considered unex-
posed. These data might therefore be expected to begin to
show the effects of both active cigarette smoking and pas-
sive secondary exposure on cord blood HPRT mutagene-
sis, although the power would not be as great as if they
were derived only from defined exposed groups.
In adults, active tobacco smoke exposure has been found
to increase the frequency and proportion of small base
changes at the HPRT gene [33], consistent with the known
mechanisms of tobacco smoke mutagens and the types of
mutations found in oncogenes in smoking-associated
cancers [34,35]. Illegitimate VDJ recombination is a
mechanism of mutagenesis unique to T- and B-lym-
phocytes, and is implicated in many of the molecular
events associated with leukemia and lymphoma [36,37].
The human HPRT gene contains cryptic sites for this DNA
splicing event, resulting in the deletion of exons 2 and 3
[31,38], and the occurrence of this type of HPRT mutation
seems to be associated with the incidence of acute lym-
phocytic leukemia in children [39]. Elevated levels of ille-
gitimate VDJ recombination have been found in workers
occupationally exposed to pesticides and herbicides [40],
especially 2,4-dichlorophenoxyacetic acid [41,42] and in
cancer patients undergoing chemotherapy [43], particu-
larly with the DNA topoisomerase inhibiting agent etopo-
side [44,45].
Overall, the two newborn populations from Vermont had
indistinguishable HPRT Mf (P = 0.50), and the total pop-
ulation data from McGinniss et al [11] was also consistent
with the unexposed group reported by Finette et al [22,23]
(P = 0.51), but the passively exposed group had a signifi-
cantly higher level of mutation (P = 0.013). The distribu-
tion of mutants among the three mechanistic classes
differed significantly in both cases, however, with the
mutants from McGinniss et al [29] exhibiting less small
mutation and more VDJ recombination-mediated dele-
tion than either group from Finette et al [22,23]. The
Colorado population had a significantly higher Mf than
the unexposed subset of the second Vermont population
(P = 0.008), but a very similar distribution of mutants (P
= 0.91). On the other hand, the Colorado population had
a similar mutation frequency as the passively exposed
subpopulation from this study (P = 0.55), but a somewhat
different mutant distribution (P = 0.068). We believe that
these mutational comparisons are of little use unless both
frequency and distribution are taken into account at the
same time. In Table 2, panels b and c, the overall HPRT Mf
from these individual studies and subpopulations (panel
b), or the Mf generated from our pooled analysis (panel c),
are used to calculate the frequency of each type of mutant
in each population, as was done in Manchester et al [21]
and Finette et al [23].
Expressing the mutational classes as frequencies makes it
easier to see the general trends in these studies and their
inconsistencies. The frequency of VDJ recombination-
mediated deletions is now increased in all exposed popu-
lations, and the results from the mixed tobacco smoke
populations are consistent with an intermediate level of
exposure (remember that even though these populations
should contain maternal active smoking exposures, and
quitters, the meta-analysis indicated that these should
have induced Mf similar to the passively exposed popula-
tion). The differences in the frequencies of non-VDJ
recombination-mediated deletions and rearrangements
are diminished under these circumstances. The increase in
frequency of small mutations observed in the passively
exposed population of Finette et al [22,23] is difficult to
rationalize with the low levels found in the McGinniss et
al [29] study, however, the induction in the Manchester et
al [21] population is again intermediate between those of
the two subpopulations from Finette et al [22,23]. Signif-
icantly, none of the decreases observed in the frequencies
of mutational subclasses from the unexposed population
of Finette et al [23] were themselves statistically
significant.
Discussion
Pooling data from studies applying similar techniques has
been shown to be a useful method of investigating subtle
effects in molecular epidemiology [46]. The present data
was derived from a limited number of studies, however,
and may contain unintended bias based on mutation
detection methods, study design or uncontrolled con-
founders. Moreover, we stress that all of this data is based
on mutation at a single locus, the X-linked HPRT gene,
which may not be representative of the entire genome [5].
All cells in the embryo undergo periods of rapid differen-
tiation and proliferation. It has long been postulated that
rapidly growing cells are at increased risk of genotoxic
damage; this idea is based on the hierarchy of tissues
affected by ionizing radiation exposure, the response of
tumors to genotoxic chemotherapy, and has been put for-
ward as a way to rationalize hormonal carcinogenesis
with the somatic mutational basis of cancer. While in uteroBMC Pediatrics 2005, 5:20 http://www.biomedcentral.com/1471-2431/5/20
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exposures have been associated with later increases in can-
cer susceptibility, this research has mostly involved agents
that interfere with the differentiation process [47], rather
than classical mutagens [48].
Conclusion
This analysis demonstrates that, despite the conclusions
of the original papers presenting the data, both active and
passive tobacco smoke exposure in utero results in
increased fetal mutation at the HPRT locus. The observed
mutational induction by passive maternal tobacco smoke
exposure clarifies the shift in the HPRT mutational spec-
trum previously reported [23], without requiring a com-
plementary protective effect of tobacco smoke on certain
types of mutation. The types of mutations observed are
consistent with the known mechanisms of tobacco smoke
mutagenesis, as well as the unique biochemistry of T-lym-
phocytes during in utero development. The establishment
of these in utero tobacco smoke effects depended not only
on the size of the pooled data set, but also on the judi-
cious selection of a control group, and should abundantly
demonstrate the long-term benefits of publishing data in
a form that allows for such a re-analysis.
The observation that tobacco smoke mutational effects
were not significantly ameliorated by quitting active
smoking after the first trimester is troubling. It may well
be consistent with the "all-or-none" quality of toxic expo-
sures early in development, although it is doubtful that
mutations arising by the mechanism of VDJ recombina-
tion-mediated deletion are possible at such an early stage
of development. A more probable explanation for the per-
sistent mutational induction observed in the quitters may
involve continued passive exposure, since smoking moth-
ers are far more likely to also be exposed to secondary
smoke in the home [49]. This question should be directly
addressed. We are presently analyzing data from another
large set of newborns. In a preliminary report of the first
third of this data maternal exposure to alcohol rather than
tobacco was associated with higher HPRT  Mf  [50],
although there was a shift in the mutational spectrum in
the children of smoking mothers consistent with those
described here [51].
Overall, these data suggest that further modification of
residential and occupational exposures may be necessary
to protect the developing fetus from tobacco smoke muta-
genesis during pregnancy. If passive exposure does as
much damage to the fetus as active smoking, it is impera-
tive that workplace protection be offered to pregnant
women, or better, to women who might or intend to
become pregnant. This protection must also be provided
in the home, where not only the mother, but any other
smoking members of the household should be encour-
aged to quit for the duration of the pregnancy (or longer),
or at least should not smoke in the presence of the preg-
nant woman.
Abbreviations
HPRT, hypoxanthine-guanine phosphoribosyltransferase;
Mf, mutation frequency.
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